338 related articles for article (PubMed ID: 19195847)
21. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
Dilla T; Möller J; O'Donohoe P; Álvarez M; Sacristán JA; Happich M; Tockhorn A
BMC Psychiatry; 2014 Dec; 14():298. PubMed ID: 25438678
[TBL] [Abstract][Full Text] [Related]
22. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES).
Dubois V; Peuskens J; Geerts P; Detraux J
Early Interv Psychiatry; 2014 Feb; 8(1):39-49. PubMed ID: 23343330
[TBL] [Abstract][Full Text] [Related]
24. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
25. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
Gaebel W; Schreiner A; Bergmans P; de Arce R; Rouillon F; Cordes J; Eriksson L; Smeraldi E
Neuropsychopharmacology; 2010 Nov; 35(12):2367-77. PubMed ID: 20686456
[TBL] [Abstract][Full Text] [Related]
26. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS).
Schreiner A; Svensson A; Wapenaar R; Cherubin P; Princet P; Serazetdinova L; Zink M
World J Biol Psychiatry; 2014 Sep; 15(7):534-45. PubMed ID: 24779526
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
28. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome.
Taylor DM; Young C; Patel MX
Int J Neuropsychopharmacol; 2006 Dec; 9(6):685-94. PubMed ID: 16939663
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia: A 3-Year Follow-Up.
Fernández-Miranda JJ; Caramés-García V; Sánchez-García A
J Clin Psychopharmacol; 2015 Dec; 35(6):630-4. PubMed ID: 26421461
[TBL] [Abstract][Full Text] [Related]
30. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.
Llorca PM; Sacchetti E; Lloyd K; Kissling W; Medori R
Int J Clin Pharmacol Ther; 2008 Jan; 46(1):14-22. PubMed ID: 18218293
[TBL] [Abstract][Full Text] [Related]
31. Explicit review of risperidone long-acting injection prescribing practice.
Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
[TBL] [Abstract][Full Text] [Related]
32. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
[TBL] [Abstract][Full Text] [Related]
33. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care.
Taylor M; Currie A; Lloyd K; Price M; Peperell K
J Psychopharmacol; 2008 Mar; 22(2):128-31. PubMed ID: 18308820
[TBL] [Abstract][Full Text] [Related]
34. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
35. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
Duncan EJ; Woolson SL; Hamer RM
Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
37. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
Lambert M; De Marinis T; Pfeil J; Naber D; Schreiner A
Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263
[TBL] [Abstract][Full Text] [Related]
38. Effect of an Institutional Medication Adherence Program for Long-Acting Injectable Risperidone on Adherence and Psychiatric Hospitalizations: Evidence from a Prospective Cohort Study.
Jalbert JJ; Rossignol M; Astruc B; Baylé F; Nordon C; Avouac B; Rouillon F; Abenhaim L; Grimaldi-Bensouda L
J Popul Ther Clin Pharmacol; 2017 May; 24(2):e61-e70. PubMed ID: 28594483
[TBL] [Abstract][Full Text] [Related]
39. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
[TBL] [Abstract][Full Text] [Related]
40. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
Schmauss M; Diekamp B; Gerwe M; Schreiner A; Ibach B
Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
